This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere securing Greater China rights to RB0026, Immunofoco resubmitting its Hong Kong IPO, Fulcrum merging with Slate Medicines, Henlius signing a US$ 322M deal with Sandoz, and KeyMed proposing a STAR Market listing. Clinical highlights feature Sunshine Guojian’s NMPA approval for anflekitug, RemeGen’s RC148 achieving up to 90% ORR in NSCLC, and Minwei Bio advancing MWN109 to Phase III for obesity.
